Quent Capital LLC Sells 315 Shares of Hologic, Inc. (NASDAQ:HOLX)

Quent Capital LLC decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 27.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 813 shares of the medical equipment provider’s stock after selling 315 shares during the period. Quent Capital LLC’s holdings in Hologic were worth $59,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of HOLX. Creative Planning boosted its stake in Hologic by 16.6% during the third quarter. Creative Planning now owns 25,430 shares of the medical equipment provider’s stock worth $2,072,000 after buying an additional 3,617 shares in the last quarter. Swedbank AB lifted its holdings in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Hologic by 14.3% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,221 shares of the medical equipment provider’s stock valued at $2,869,000 after acquiring an additional 4,411 shares in the last quarter. Wolff Wiese Magana LLC bought a new stake in Hologic in the third quarter valued at about $25,000. Finally, Bleakley Financial Group LLC raised its position in Hologic by 23.9% in the third quarter. Bleakley Financial Group LLC now owns 6,368 shares of the medical equipment provider’s stock worth $519,000 after purchasing an additional 1,227 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HOLX. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Finally, Jefferies Financial Group initiated coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $85.77.

Insider Buying and Selling at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.88% of the company’s stock.

Hologic Stock Performance

HOLX stock opened at $63.62 on Friday. The company has a 50 day moving average price of $71.28 and a 200 day moving average price of $77.37. Hologic, Inc. has a fifty-two week low of $63.39 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 3.03. The stock has a market capitalization of $14.36 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts forecast that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.